EA026456B1 - Фармацевтическая композиция на основе антагониста crth2 и ингибитора протонного насоса для лечения эозинофильного эзофагита - Google Patents

Фармацевтическая композиция на основе антагониста crth2 и ингибитора протонного насоса для лечения эозинофильного эзофагита Download PDF

Info

Publication number
EA026456B1
EA026456B1 EA201491008A EA201491008A EA026456B1 EA 026456 B1 EA026456 B1 EA 026456B1 EA 201491008 A EA201491008 A EA 201491008A EA 201491008 A EA201491008 A EA 201491008A EA 026456 B1 EA026456 B1 EA 026456B1
Authority
EA
Eurasian Patent Office
Prior art keywords
methyl
fluoro
acetic acid
methylindol
indol
Prior art date
Application number
EA201491008A
Other languages
English (en)
Russian (ru)
Other versions
EA201491008A1 (ru
Inventor
Марк Энтони Пэйтон
Эрик Рой Петтифер
Original Assignee
Атопикс Терапьютикс Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Атопикс Терапьютикс Лимитед filed Critical Атопикс Терапьютикс Лимитед
Publication of EA201491008A1 publication Critical patent/EA201491008A1/ru
Publication of EA026456B1 publication Critical patent/EA026456B1/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/405Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/475Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244Interleukins [IL]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EA201491008A 2011-12-16 2012-12-14 Фармацевтическая композиция на основе антагониста crth2 и ингибитора протонного насоса для лечения эозинофильного эзофагита EA026456B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161576640P 2011-12-16 2011-12-16
PCT/GB2012/000904 WO2013088109A1 (en) 2011-12-16 2012-12-14 Combination of crth2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis

Publications (2)

Publication Number Publication Date
EA201491008A1 EA201491008A1 (ru) 2015-02-27
EA026456B1 true EA026456B1 (ru) 2017-04-28

Family

ID=47470031

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201491008A EA026456B1 (ru) 2011-12-16 2012-12-14 Фармацевтическая композиция на основе антагониста crth2 и ингибитора протонного насоса для лечения эозинофильного эзофагита

Country Status (14)

Country Link
US (1) US20140328861A1 (cg-RX-API-DMAC7.html)
EP (1) EP2790696A1 (cg-RX-API-DMAC7.html)
JP (1) JP2015500326A (cg-RX-API-DMAC7.html)
KR (1) KR20140113667A (cg-RX-API-DMAC7.html)
CN (1) CN104114169A (cg-RX-API-DMAC7.html)
AU (1) AU2012351342A1 (cg-RX-API-DMAC7.html)
BR (1) BR112014014558A8 (cg-RX-API-DMAC7.html)
CA (1) CA2859284A1 (cg-RX-API-DMAC7.html)
EA (1) EA026456B1 (cg-RX-API-DMAC7.html)
IL (1) IL233131A0 (cg-RX-API-DMAC7.html)
MX (1) MX2014007239A (cg-RX-API-DMAC7.html)
SG (1) SG11201402796SA (cg-RX-API-DMAC7.html)
UA (1) UA112667C2 (cg-RX-API-DMAC7.html)
WO (1) WO2013088109A1 (cg-RX-API-DMAC7.html)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
GB201103837D0 (en) 2011-03-07 2011-04-20 Oxagen Ltd Amorphous (5-Fluoro-2-Methyl-3-Quinolin-2-Ylmethyl-Indol-1-Yl)-acetic acid
GB201121557D0 (en) 2011-12-15 2012-01-25 Oxagen Ltd Process
CN104755495A (zh) 2012-08-21 2015-07-01 赛诺菲 通过施用il-4r拮抗剂治疗或预防哮喘的方法
RU2698907C2 (ru) 2012-09-07 2019-09-02 Ридженерон Фармасьютикалз, Инк. Способы лечения атопического дерматита с помощью антагониста il-4r
TWI633891B (zh) 2013-06-04 2018-09-01 再生元醫藥公司 藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法
PL3010539T3 (pl) 2013-06-21 2020-01-31 Sanofi Biotechnology Sposoby leczenia polipowatości nosa przez podawanie antagonisty il-4r
TWI634900B (zh) 2013-07-11 2018-09-11 再生元醫藥公司 藉由投與il-4r抑制劑治療嗜酸性食道炎的方法
WO2015034678A2 (en) 2013-09-06 2015-03-12 Aptalis Pharmatech, Inc. Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis
MX376691B (es) 2014-02-28 2025-03-07 Regeneron Pharma Composición farmaceutica que comprende un antagonista de il-4r para tratar una infección cutánea.
GB201407807D0 (en) 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
GB201407820D0 (en) 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
KR20230158131A (ko) 2014-11-14 2023-11-17 사노피 바이오테크놀로지 Il-4r 길항제의 투여에 의한, 비용종을 동반한 만성 부비동염의 치료 방법
ES2991300T3 (es) 2015-02-13 2024-12-03 Inserm Institut Nat De La Sante Et De Larecherche Medicale Antagonistas de PTGDR-1 y/o PTGDR-2 para prevenir y/o tratar lupus eritematoso sistémico
EP3402572B1 (en) 2016-01-13 2022-03-16 Children's Hospital Medical Center Compositions and methods for treating allergic inflammatory conditions
US10800765B2 (en) 2016-07-21 2020-10-13 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Indole derivative used as CRTH2 inhibitor
TWI777515B (zh) * 2016-08-18 2022-09-11 美商愛戴爾製藥股份有限公司 治療嗜伊紅性食道炎之方法
PT3506931T (pt) 2016-09-01 2024-08-21 Regeneron Pharma Métodos de prevenção ou de tratamento da alergia mediante a administração de um antagonista de il-4r
WO2019028367A1 (en) 2017-08-04 2019-02-07 Regeneron Pharmaceuticals, Inc. METHODS OF TREATING ESOPHAGITIS WITH ACTIVE EOSINOPHILES
PT3515465T (pt) 2017-08-18 2024-03-04 Regeneron Pharma Métodos para o tratamento de uma dermatite atópica grave mediante a administração de um inibidor de il-4r
KR102694419B1 (ko) 2017-10-30 2024-08-09 사노피 바이오테크놀로지 Il-4r 길항제를 투여하여 천식을 치료 또는 예방하는 방법
CN107987066B (zh) * 2017-11-30 2020-06-26 正大天晴药业集团股份有限公司 作为crth2抑制剂的吲哚衍生物
CN107936004B (zh) * 2017-11-30 2020-05-05 正大天晴药业集团股份有限公司 作为crth2抑制剂的吲哚类衍生物
CN107954995B (zh) * 2017-11-30 2020-05-05 正大天晴药业集团股份有限公司 具有crth2抑制剂活性的吲哚衍生物
CN107987072B (zh) * 2017-11-30 2020-06-26 正大天晴药业集团股份有限公司 作为crth2抑制剂的吲哚类化合物
US11859250B1 (en) 2018-02-23 2024-01-02 Children's Hospital Medical Center Methods for treating eosinophilic esophagitis
US12360103B2 (en) 2018-04-20 2025-07-15 Children's Hospital Medical Center Blood biomarker for eosinophilic gastrointestinal disorders
SG11202009371WA (en) 2018-05-13 2020-10-29 Regeneron Pharma Methods for treating atopic dermatitis by administering an il-4r inhibitor
US12297501B2 (en) 2019-02-25 2025-05-13 Children's Hospital Medical Center Methods for diagnosing and treating eosinophilic gastritis
KR20210143246A (ko) 2019-03-21 2021-11-26 리제너론 파아마슈티컬스, 인크. 알레르기 치료용 il-4/il-13 경로 억제제 및 형질 세포 절제의 병용
US12398212B2 (en) 2019-07-16 2025-08-26 Sanofi Biotechnology Methods for treating or preventing asthma by administering an IL-4R antagonist
CN114173816A (zh) 2019-08-05 2022-03-11 瑞泽恩制药公司 通过施用il-4r拮抗剂治疗特应性皮炎的方法
CN114173819A (zh) 2019-08-05 2022-03-11 瑞泽恩制药公司 通过施用il-4r拮抗剂治疗过敏和增强过敏原特异性免疫疗法的方法
WO2022020464A1 (en) * 2020-07-21 2022-01-27 Ellodi Pharmaceuticals, L.P. Modified release rapidly disintegrating compositions of proton pump inhibitors
EP4595953A1 (en) * 2024-01-30 2025-08-06 Dr. Falk Pharma Gmbh Orally applicable suspension for the treatment of eosinophilic esophagitis in children

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010039982A1 (en) * 2008-10-01 2010-04-08 Ironwood Pharmaceuticals, Inc. Crth2 modulators
WO2010042652A2 (en) * 2008-10-08 2010-04-15 Amira Pharmaceuticals, Inc. Heteroalkyl biphenyl antagonists of prostaglandin d2 receptors
US20110124683A1 (en) * 2007-11-13 2011-05-26 Oxagen Limited Use of CRTH2 Antagonist Compounds

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE416649B (sv) 1974-05-16 1981-01-26 Haessle Ab Forfarande for framstellning av foreningar som paverkar magsyrasekretionen
IL75400A (en) 1984-06-16 1988-10-31 Byk Gulden Lomberg Chem Fab Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same
JPS6150978A (ja) 1984-08-16 1986-03-13 Takeda Chem Ind Ltd ピリジン誘導体およびその製造法
GB2189699A (en) 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
FI90544C (fi) 1986-11-13 1994-02-25 Eisai Co Ltd Menetelmä lääkeaineina käyttökelpoisten 2-pyridin-2-yyli-metyylitio- ja sulfinyyli-1H-bensimidatsolijohdannaisten valmistamiseksi
JPH0768125B2 (ja) 1988-05-18 1995-07-26 エーザイ株式会社 酸不安定化合物の内服用製剤
SE9301830D0 (sv) 1993-05-28 1993-05-28 Ab Astra New compounds
TWI275587B (en) 1999-06-17 2007-03-11 Takeda Chemical Industries Ltd A crystal of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole
SE0200411D0 (sv) 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
SE0200356D0 (sv) 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
EP1505061A4 (en) 2002-05-16 2007-08-22 Shionogi & Co CONNECTION WITH PGD-2 RECEPTOR ANTAGONISM
AU2003231513A1 (en) 2002-05-16 2003-12-02 Shionogi And Co., Ltd. Pgd2 receptor antagonist
SE0201635D0 (sv) 2002-05-30 2002-05-30 Astrazeneca Ab Novel compounds
TW200307542A (en) 2002-05-30 2003-12-16 Astrazeneca Ab Novel compounds
SE0202241D0 (sv) 2002-07-17 2002-07-17 Astrazeneca Ab Novel Compounds
MXPA05003456A (es) 2002-10-04 2005-07-05 Millennium Pharm Inc Antagonistas del receptor de pgd2 para el tratamiento de enfermedades inflamatorias.
WO2004035543A1 (en) 2002-10-21 2004-04-29 Warner-Lambert Company Llc Tetrahydroquinoline derivatives as crth2 antagonists
US7321001B2 (en) 2002-12-20 2008-01-22 Amgen Inc. Asthma and allergic inflammation modulators
SE0301009D0 (sv) 2003-04-07 2003-04-07 Astrazeneca Ab Novel compounds
SE0301010D0 (sv) 2003-04-07 2003-04-07 Astrazeneca Ab Novel compounds
PT1471057E (pt) 2003-04-25 2006-05-31 Actimis Pharmaceuticals Inc Derivados de acido pirimidinilacetico uteis para o tratamento de doencas mediadas por crth2
SE0301569D0 (sv) 2003-05-27 2003-05-27 Astrazeneca Ab Novel compounds
WO2005007094A2 (en) 2003-07-09 2005-01-27 Tularik Inc. Asthma and allergic inflammation modulators
SE0302232D0 (sv) 2003-08-18 2003-08-18 Astrazeneca Ab Novel Compounds
SA04250253B1 (ar) 2003-08-21 2009-11-10 استرازينيكا ايه بي احماض فينوكسي اسيتيك مستبدلة باعتبارها مركبات صيدلانية لعلاج الامراض التنفسية مثل الربو ومرض الانسداد الرئوي المزمن
WO2005040112A1 (en) 2003-10-14 2005-05-06 Oxagen Limited Compounds with pgd2 antagonist activity
CA2542716A1 (en) 2003-10-14 2005-05-06 Oxagen Limited Compounds having crth2 antagonist activity
GB0324763D0 (en) 2003-10-23 2003-11-26 Oxagen Ltd Use of compounds in therapy
SE0303180D0 (sv) 2003-11-26 2003-11-26 Astrazeneca Ab Novel compounds
NZ548396A (en) 2004-01-31 2010-06-25 Actimis Pharmaceuticals Inc Imidazo[1,2-C]pyrimidinylacetic acid derivatives
ATE394399T1 (de) 2004-03-11 2008-05-15 Actelion Pharmaceuticals Ltd Tetrahydropyridoindolderivate
RU2376286C2 (ru) 2004-03-11 2009-12-20 Актелион Фармасьютиклз Лтд Производные индол-1-илуксусной кислоты
BRPI0509668A (pt) 2004-04-07 2007-10-09 Millennium Pharm Inc composto, composição farmacêutica que compreende o mesmo, método de tratamento de enfermidade, distúrbio ou sintoma inflamatório e método de preparação do composto
US20050234030A1 (en) 2004-04-20 2005-10-20 Wilmin Bartolini Modulators of CRTH2, COX-2 and FAAH
GB0409921D0 (en) 2004-05-04 2004-06-09 Novartis Ag Organic compounds
EA200602288A1 (ru) 2004-05-29 2007-10-26 7ТиЭм ФАРМА А/С Замещённые тиазолуксусные кислоты в качестве лигандов crth2
EP1758579A1 (en) 2004-05-29 2007-03-07 7TM Pharma A/S Crth2 receptor ligands for medicinal uses
WO2005115374A1 (en) 2004-05-29 2005-12-08 7Tm Pharma A/S Crth2 receptor ligands for therapeutic use
MY144903A (en) 2004-06-17 2011-11-30 Novartis Ag Pyrrolopyridine derivatives and their use as crth2 antagonists
GB0415320D0 (en) 2004-07-08 2004-08-11 Astrazeneca Ab Novel compounds
GB0418830D0 (en) 2004-08-24 2004-09-22 Astrazeneca Ab Novel compounds
AU2005286718A1 (en) 2004-09-21 2006-03-30 Wyeth Indole acetic acids exhibiting CRTH2 receptor antagonism and uses thereof
GB0422057D0 (en) 2004-10-05 2004-11-03 Astrazeneca Ab Novel compounds
ATE517085T1 (de) 2004-11-23 2011-08-15 Astrazeneca Ab Zur behandlung von atemwegserkrankungen geeignete phenoxyessigsäurederivate
GB0427381D0 (en) 2004-12-14 2005-01-19 Novartis Ag Organic compounds
GB0500604D0 (en) 2005-01-13 2005-02-16 Astrazeneca Ab Novel process
CA2598133A1 (en) 2005-02-24 2006-08-31 Millennium Pharmaceuticals, Inc. Pgd2 receptor antagonists for the treatment of inflammatory diseases
GB0505048D0 (en) 2005-03-11 2005-04-20 Oxagen Ltd Compounds with PGD antagonist activity
ES2369714T3 (es) 2005-04-21 2011-12-05 Merck Serono Sa Pirazina sulfonamidas 2,3 sustituidas como inhibidores de crth2.
GB0510584D0 (en) 2005-05-24 2005-06-29 Novartis Ag Organic compounds
GB0510585D0 (en) 2005-05-24 2005-06-29 Novartis Ag Organic compounds
JP5567268B2 (ja) 2005-05-24 2014-08-06 メルク セローノ ソシエテ アノニム Crth2の調節剤としての三環系スピロ誘導体
GB0512944D0 (en) 2005-06-24 2005-08-03 Argenta Discovery Ltd Indolizine compounds
EP1747800B1 (en) * 2005-07-29 2009-03-18 Rottapharm S.p.A. Combination of itriglumide and proton pump inhibitors in the treatment of gastrointestinal and related disorders
JP4972644B2 (ja) 2005-08-12 2012-07-11 メルク カナダ インコーポレイテッド Crth2受容体拮抗薬としてのインドール誘導体
WO2007022501A2 (en) 2005-08-18 2007-02-22 Microbia, Inc. Useful indole compounds
GB0518494D0 (en) 2005-09-09 2005-10-19 Argenta Discovery Ltd Thiazole compounds
GB0518783D0 (en) 2005-09-14 2005-10-26 Argenta Discovery Ltd Indolizine compounds
AU2006296397B2 (en) 2005-09-30 2011-12-15 Gb001, Inc. Quinolines and their therapeutic use
EP1937632A1 (en) 2005-10-06 2008-07-02 Astra Zeneca AB Novel compounds
TW200745003A (en) 2005-10-06 2007-12-16 Astrazeneca Ab Novel compounds
GB0521275D0 (en) 2005-10-19 2005-11-30 Argenta Discovery Ltd 3-Aminoindole compounds
JP2009514935A (ja) 2005-11-05 2009-04-09 アストラゼネカ・アクチエボラーグ 新規化合物
WO2007062678A1 (en) 2005-11-29 2007-06-07 7Tm Pharma A/S Phenoxyacetic acid derivatives as crth2 receptor ligands
GB0524427D0 (en) 2005-11-30 2006-01-11 7Tm Pharma As Use of receptor ligands in threapy
WO2007062677A1 (en) 2005-11-30 2007-06-07 7Tm Pharma A/S Thiazolyl- and pyrimidinyl-acetic acids and their use as crth2 receptor ligands
GB0524428D0 (en) 2005-11-30 2006-01-11 7Tm Pharma As Medicinal use of receptor ligands
EP2305640A3 (en) 2005-12-15 2011-07-20 AstraZeneca AB Substituted diphenyl-ethers, -amines, -sulfides and -methanes for the treatment of respiratory diseases
JP2009538289A (ja) 2006-05-26 2009-11-05 アストラゼネカ・アクチエボラーグ ビアリールまたはヘテロアリール置換インドール
GB0611781D0 (en) 2006-06-14 2006-07-26 Argenta Discovery Ltd 2-Oxo-2H-Chromene Compounds
MX2009000801A (es) 2006-07-22 2009-02-03 Oxagen Ltd Compuestos que tienen actividad antagonista crth2.
MX2009001876A (es) 2006-08-21 2009-03-06 Array Biopharma Inc Derivados de acido fenoxifenilacetico 4-sustituidos.
EA200970590A1 (ru) 2006-12-21 2009-12-30 Арджента Дискавери Лимитед Антагонисты crth2
GB0625842D0 (en) 2006-12-22 2007-02-07 Argenta Discovery Ltd Indolizine derivatives
MX2009010068A (es) 2007-03-21 2010-02-24 Argenta Oral Therapeutics Ltd Derivados de acido indolizin acetico como antagonistas de crth2.
EP2129661B1 (en) 2007-03-29 2012-02-08 Pulmagen Therapeutics (Asthma) Limited Quinoline derivatives as crth2 receptor ligands
CN102875478A (zh) 2007-06-21 2013-01-16 艾克提麦斯医药品有限公司 一种crth2 拮抗剂的胺盐
GB0722216D0 (en) * 2007-11-13 2007-12-27 Oxagen Ltd Use of crth2 antagonist compounds
EA017573B1 (ru) * 2007-12-14 2013-01-30 Пульмаджен Терапьютикс (Эсме) Лимитед Производные индол-1-илуксусной кислоты и их терапевтическое применение
CA2707789A1 (en) 2007-12-19 2009-07-09 Amgen Inc. Phenyl acetic acid derivatives as inflammation modulators
DK2250161T3 (da) * 2008-01-18 2014-01-27 Atopix Therapeutics Ltd Forbindelser med CRTH2-antagonistaktivitet
US7750027B2 (en) 2008-01-18 2010-07-06 Oxagen Limited Compounds having CRTH2 antagonist activity
EP2240444A1 (en) 2008-01-22 2010-10-20 Oxagen Limited Compounds having crth2 antagonist activity
WO2009093026A1 (en) 2008-01-22 2009-07-30 Oxagen Limited Compounds having crth2 antagonist activity
EP2300425A4 (en) * 2008-06-24 2012-03-21 Panmira Pharmaceuticals Llc PROSTAGLANDIN D2 RECEPTOR CYCLOALCANEÝBINDLUCK ANTAGONISTS
JP2012072061A (ja) * 2009-01-29 2012-04-12 Eisai R & D Management Co Ltd 新規組成物
EP2456439A4 (en) * 2009-07-20 2012-12-26 Vetegen Llc STABLE PHARMACEUTICAL OMEPRAZOLE FORMULATION FOR ORAL ADMINISTRATION
SG178252A1 (en) 2009-08-05 2012-03-29 Panmira Pharmaceuticals Llc Dp2 antagonist and uses thereof
KR20120090931A (ko) * 2009-08-17 2012-08-17 더 리전트 오브 더 유니버시티 오브 캘리포니아 심혈관 및 대사성 질환, 예컨대 제2형 당뇨병의 치료를 위한 nkg2d 억제제의 용도
PH12012501349A1 (en) 2010-01-06 2013-01-14 Panmira Pharmaceuticals Llc Dp2 antagonist and uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110124683A1 (en) * 2007-11-13 2011-05-26 Oxagen Limited Use of CRTH2 Antagonist Compounds
WO2010039982A1 (en) * 2008-10-01 2010-04-08 Ironwood Pharmaceuticals, Inc. Crth2 modulators
WO2010042652A2 (en) * 2008-10-08 2010-04-15 Amira Pharmaceuticals, Inc. Heteroalkyl biphenyl antagonists of prostaglandin d2 receptors

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
A. STRAUMANN, HOESLI S., BUSSMANN CH., STUCK M., PERKINS M., COLLINS L. P., PAYTON M., PETTIPHER R., HUNTER M., STEINER J., SIMON : "Anti-eosinophil activity and clinical efficacy of the CRTH2 antagonist OC000459 in eosinophilic esophagitis", ALLERGY, MUNKSGAARD., vol. 68, no. 3, 1 March 2013 (2013-03-01), pages 375 - 385, XP055054697, ISSN: 01054538, DOI: 10.1111/all.12096 *
JAVIER MOLINA INFANTE; LUCIA FERRANDO LAMANA; CRISTINA RIPOLL; MOISES HERNANDEZ ALONSO; JOSE M. MATEOS; MIGUEL FERNANDEZ BERMEJO; : "Esophageal Eosinophilic Infiltration Responds to Proton Pump Inhibition in Most Adults", CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, AMERICAN GASTROENTEROLOGICAL ASSOCIATION,, US, vol. 9, no. 2, US, pages 110 - 117, XP028187339, ISSN: 1542-3565, DOI: 10.1016/j.cgh.2010.09.019 *
KATHRYN A. PETERSON ; KRISTEN L. THOMAS ; KRISTEN HILDEN ; LYSKA L. EMERSON ; JASON C. WILLS ; JOHN C. FANG: "Comparison of Esomeprazole to Aerosolized, Swallowed Fluticasone for Eosinophilic Esophagitis", DIGESTIVE DISEASES AND SCIENCES, KLUWER ACADEMIC PUBLISHERS-PLENUM PUBLISHERS, NE, vol. 55, no. 5, 18 June 2009 (2009-06-18), Ne, pages 1313 - 1319, XP019816553, ISSN: 1573-2568 *

Also Published As

Publication number Publication date
US20140328861A1 (en) 2014-11-06
KR20140113667A (ko) 2014-09-24
AU2012351342A1 (en) 2014-07-24
CN104114169A (zh) 2014-10-22
EA201491008A1 (ru) 2015-02-27
MX2014007239A (es) 2014-08-08
UA112667C2 (uk) 2016-10-10
SG11201402796SA (en) 2014-06-27
BR112014014558A8 (pt) 2017-07-04
CA2859284A1 (en) 2013-06-20
JP2015500326A (ja) 2015-01-05
WO2013088109A1 (en) 2013-06-20
IL233131A0 (en) 2014-07-31
BR112014014558A2 (pt) 2017-06-13
EP2790696A1 (en) 2014-10-22
NZ626990A (en) 2016-01-29

Similar Documents

Publication Publication Date Title
EA026456B1 (ru) Фармацевтическая композиция на основе антагониста crth2 и ингибитора протонного насоса для лечения эозинофильного эзофагита
TWI607754B (zh) 醫藥組合
KR20180006447A (ko) Braf-v600-관련 질환의 치료에 사용하기 위한 plx-8394 또는 plx-7904
US20110124683A1 (en) Use of CRTH2 Antagonist Compounds
TWI873485B (zh) 用於治療癌症之方法及包含cdk2抑制劑及cdk4抑制劑之給藥方案
AU2018234903B2 (en) Combination therapies for the treatment of breast cancer
CN101522187A (zh) 用于治疗、减轻、改善或缓解后段眼病的组合物和方法
JP2000198734A (ja) 胃運動性減弱および関連疾患の治療のための運動性増強薬
JP2005503382A (ja) 偏頭痛の治療のために他の抗偏頭痛薬と組み合わせたbibn4096の使用
EP3856187A1 (en) Infigratinib for treatment of fgfr3-related skeletal diseases during pregnancy
EP2914264B1 (en) A 6-oxo-1,6-dihydro-pyridazine derivative for the use for the treatment of hepatocellular carcinoma (hcc)
US9511068B2 (en) Composition for treating or preventing diseases caused by vascular permeability, containing imatinib or pharmaceutically acceptable salt thereof as active ingredient
EP1713543B1 (fr) Utilisation de derives d'indolizine 1,2,3 substitues pour le traitement de maladies liees a une angiogenese pathologique choroidienne
JP2005047909A (ja) ピペリジン誘導体を有効成分とする掻痒治療剤
CN114746093A (zh) 治疗血管畸形的方法
WO2015055974A1 (en) Proton pump inhibitor paste compositions
JP2022500351A (ja) 疼痛使用のためのch24h阻害剤
JP7395358B2 (ja) mTOR経路の調節異常に関連する疾患の治療
CN1466587A (zh) 含有2-芳基-8-氧代二氢嘌呤衍生物作为活性成分的痴呆症治疗剂
JP2008255008A (ja) 滑膜細胞増殖抑制剤
GB2524351A (en) Proton Pump Inhibitor Paste Compositions